Showing results (1-10 of 28) with videos related to
Sort By:
Pageof 3
Expert Opinion on Biological Therapy|February 24, 2010
Figitumumab (CP-751,871) for cancer therapyAntonio GualbertoExpert Opinion on Investigational Drugs|December 1, 2011
Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignanciesAntonio GualbertoCurrent Drug Targets|August 12, 2009
Clinical development of inhibitors of the insulin-like growth factor receptor in oncologyAntonio Gualberto, Michael PollakClinical Lung Cancer|July 28, 2009
Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients with non-small-cell lung cancerAntonio Gualberto, Daniel D KarpCell Cycle (Georgetown, Tex.)|April 16, 2003
Vascular smooth muscle polyploidization--from mitotic checkpoints to hypertensionMary L Hixon, Antonio GualbertoJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2010
The evolving role of histology in the management of advanced non-small-cell lung cancerCorey J Langer, Benjamin Besse, Antonio Gualberto, et al.Reviews on Recent Clinical Trials|June 11, 2010
Development of inhibitors of the IGF-IR/PI3K/Akt/mTOR pathwayMary L Hixon, Luisa Paccagnella, Robert Millham, et al.Cell Cycle (Georgetown, Tex.)|May 8, 2003
Loss of mitotic spindle checkpoint activity predisposes to chromosomal instability at early stages of fibrosarcoma developmentDuncan M Gascoyne, Mary L Hixon, Antonio Gualberto, et al.Cancer Chemotherapy and Pharmacology|August 4, 2009
Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinomaPaul Haluska, Frank Worden, David Olmos, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2020
A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring HRAS MutationsHye Won Lee, Jason K Sa, Antonio Gualberto, et al.Pageof 3